Verrica YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from FDA

 NCE status provides a minimum of five years of regulatory exclusivity

The Company’s U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension

https://www.globenewswire.com/news-release/2024/03/26/2852256/0/en/Verrica-Pharmaceuticals-Announces-that-YCANTH-Receives-New-Chemical-Entity-Status-and-Orange-Book-Listing-from-the-FDA.html